Lymphatic Osteopathic Manipulative Medicine to Enhance Coronavirus (COVID-19) Vaccination Efficacy

Not Applicable

Withdrawn

• Conditions: COVID-19
• Interventions: Other: Lymphatic OMM; Other: Light Touch

• Registration Number: NCT05069636
• Lead Sponsor: Rowan University

Brief Summary

The purpose of this project is to study the impact of Osteopathic Manipulative Medicine (OMM) treatments, such as lymphatic myofascial release and thoracic pump techniques severe acute respiratory syndrome-associated coronavirus 2 (SARS-Cov-2) antibody levels in patients who receive the mRNA-1273 (Moderna) COVID-19 vaccine and to consider if these OMM strategies allow a stronger more robust immune response.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-02-14
• Study First Submitted: 2021-09-29
• Study First Submitted QC: 2021-10-04
• Study First Posted: 2021-10-06
• Status Verified: 2022-09
• Last Update Submitted: 2022-09-30
• Last Update Posted: 2022-10-03
• Primary Completion: 2023-02-28
• Study Completion: 2023-02-28

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Inclusion criteria will include age greater than 18 years old and having safely received the COVID-19 vaccine.

Exclusion Criteria

• Exclusion criteria will include age under 18 years old, malignancy/cancer, ongoing infection, coagulopathy history, use of anticoagulant medications, and fracture or acute injury of the torso neck or upper extremities. Lymphatic OMM is safe during pregnancy and this does not need to be an exclusion criteria.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Lymphatic OMM plus Moderna COVID-19 Vaccine regimen	Lymphatic OMM	Patients receive OMM treatments that will include thoracic inlet and outlet myofascial release, pectoral traction myofascial release, and Miller Thoracic Lymphatic Pump technique plus the Moderna COVID-19 Vaccine regimen.
Light Touch plus Moderna COVID-19 Vaccine regimen	Light Touch	Patients receive a series of light touch techniques plus the Moderna COVID-19 Vaccine regimen.

Primary Outcome Measures

Name	Time	Method
severe acute respiratory syndrome-associated coronavirus 2 (SARS-Cov-2) antibody levels	The day of first vaccine dose (baseline), the day of second vaccine dose (at about 4-weeks post first vaccine dose), and 2-weeks post second vaccine dose (at about 6-weeks post first vaccine dose	Antibody levels collected via blood draw

Trial Locations

Locations (1)

Rowan University School of Osteopathic Medicine; 🇺🇸 Stratford, New Jersey, United States